ArticleSurgical endoscopy2026
The impact of semaglutide initiated six months after laparoscopic sleeve gastrectomy on long-term weight loss and metabolic outcomes: single-center preliminary study.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough laparoscopic sleeve gastrectomy (LSG) is an effective treatment for severe obesity, some patients experience suboptimal weight loss or an early weight-loss plateau during postoperative follow-up. Semaglutide has emerged as an effective pharmacological option for obesity management; however, evidence regarding its use after bariatric surgery remains limited. This study evaluated the impact of adjunctive semaglutide therapy initiated six months after LSG on long-term weight loss and metabolic outcomes. MATERIALS AND
methodsThis retrospective single-center study included 88 patients who underwent primary LSG. Patients were divided into two groups: 45 patients underwent standard postoperative follow-up after LSG, whereas 43 patients received adjunctive semaglutide therapy initiated six months after surgery because of suboptimal weight loss or weight-loss plateau. Anthropometric and metabolic parameters, including body weight, body mass index (BMI), percentage of total weight loss (%TWL), percentage of excess weight loss (%EWL), glycated hemoglobin (HbA1c), lipid profile, and blood pressure, were evaluated at baseline and at 6, 12, and 24 months after surgery.
resultsNo significant differences were observed between the groups six months after surgery, immediately before semaglutide initiation. At 12 months, patients receiving semaglutide achieved significantly lower BMI, lower body weight, and greater %TWL and %EWL. These benefits persisted at 24 months, with significantly greater weight loss and a more favorable metabolic profile, including higher HDL cholesterol and lower total cholesterol and triglyceride concentrations.
conclusionsAdjunctive semaglutide therapy initiated six months after laparoscopic sleeve gastrectomy was associated with significantly greater long-term weight loss and improved cardiometabolic outcomes compared with surgery alone. These findings suggest that postoperative semaglutide may represent an effective and safe strategy for patients experiencing suboptimal weight loss following sleeve gastrectomy.
Indexed as
Identifiers
42850299What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.